Compare Gilead Sciences, Inc. (GILD) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kinross Gold Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while Kinross Gold Corporation trades at $23 (market cap $27.94B). The key difference: Gilead Sciences, Inc. is far larger — about 5.9× Kinross Gold Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | KGC | |
|---|---|---|
Market Cap | $163.51B | $27.94B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $38.06 |
52-Week Low | $108.22 | $15.33 |
Enterprise Value | $178.05B | $26.49B |
Dividend Yield | 2.49% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Kinross Gold (KGC) trades at $23.91, up 1.83% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals, with Q1 2026 EPS of $0.71 beating expectations and robust profitability margins. Revenue grew to $7.05 billion in 2025, with net income reaching $2.39 billion. Recent news highlights exploration updates and Q2 2026 results due July 29, 2026.
KGC presents a compelling value with a P/E of 10.07 and consensus price target of $37.20, implying significant upside. Strengths include strong cash flow growth and a healthy balance sheet. Risks involve potential margin pressure from rising costs and gold price volatility. Analyst sentiment is bullish with 59% buy ratings, supporting a positive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
